company background image
3320 logo

China Resources Pharmaceutical Group SEHK:3320 Voorraadrapport

Laatste prijs

HK$6.29

Marktkapitalisatie

HK$39.5b

7D

22.1%

1Y

26.8%

Bijgewerkt

02 Oct, 2024

Gegevens

Financiële gegevens bedrijf +

China Resources Pharmaceutical Group Limited

SEHK:3320 Voorraadrapport

Marktkapitalisatie: HK$39.5b

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

3320 Overzicht aandelen

China Resources Pharmaceutical Group Limited, een investeringsholding, houdt zich bezig met onderzoek en ontwikkeling, productie, distributie en verkoop van farmaceutische en andere gezondheidsproducten op het Chinese vasteland en daarbuiten.

Over het bedrijf

Beloningen

Verhandeld tegen 72.7% onder onze schatting van de reële waarde
De winst zal naar verwachting met 7.34% per jaar groeien
De winst groeide het afgelopen jaar met 11.7%

Risicoanalyse

Heeft een hoog schuldenniveau

China Resources Pharmaceutical Group Limited Concurrenten

CSPC Pharmaceutical Group

SEHK:1093

HK$74.9b

China Traditional Chinese Medicine Holdings

SEHK:570

HK$22.1b

Grand Pharmaceutical Group

SEHK:512

HK$18.3b

United Laboratories International Holdings

SEHK:3933

HK$19.2b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor China Resources Pharmaceutical Group
Historische aandelenkoersen
Huidige aandelenkoersHK$6.29
52 Week HoogtepuntHK$6.40
52 Week LaagHK$4.45
Bèta0.39
11 maand verandering16.05%
3 maanden verandering10.16%
1 Jaar Verandering26.81%
33 jaar verandering66.84%
5 jaar verandering-14.54%
Verandering sinds IPO-30.19%

Recent nieuws en updates

Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly

Aug 30
Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly

Recent updates

Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly

Aug 30
Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly

China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697

Jun 01
China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697

Subdued Growth No Barrier To China Resources Pharmaceutical Group Limited (HKG:3320) With Shares Advancing 32%

May 13
Subdued Growth No Barrier To China Resources Pharmaceutical Group Limited (HKG:3320) With Shares Advancing 32%

China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697

Apr 28
China Resources Pharmaceutical Group (HKG:3320) Will Pay A Larger Dividend Than Last Year At CN¥0.1697

China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697

Apr 14
China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697

China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697

Mar 28
China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697

China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon

Jan 28
China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon

We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt

Dec 06
We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt

Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?

Sep 07
Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?

Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?

Aug 02
Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?

With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case

May 26
With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case

These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well

May 05
These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well

China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year

Apr 04
China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year

Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?

Jan 24
Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?

Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?

Dec 15
Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?

China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price

Oct 18
China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price

China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt

Aug 27
China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt

China Resources Pharmaceutical Group (HKG:3320) Has Announced That It Will Be Increasing Its Dividend To HK$0.15

May 29
China Resources Pharmaceutical Group (HKG:3320) Has Announced That It Will Be Increasing Its Dividend To HK$0.15

China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To HK$0.15

May 02
China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To HK$0.15

China Resources Pharmaceutical Group's (HKG:3320) Upcoming Dividend Will Be Larger Than Last Year's

Apr 07
China Resources Pharmaceutical Group's (HKG:3320) Upcoming Dividend Will Be Larger Than Last Year's

China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet

Mar 31
China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet

Are Investors Undervaluing China Resources Pharmaceutical Group Limited (HKG:3320) By 23%?

Feb 21
Are Investors Undervaluing China Resources Pharmaceutical Group Limited (HKG:3320) By 23%?

Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly

Dec 07
Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly

China Resources Pharmaceutical Group Limited (HKG:3320) Shares Could Be 32% Below Their Intrinsic Value Estimate

Nov 10
China Resources Pharmaceutical Group Limited (HKG:3320) Shares Could Be 32% Below Their Intrinsic Value Estimate

These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well

Aug 29
These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well

Is China Resources Pharmaceutical Group Limited (HKG:3320) Trading At A 21% Discount?

Aug 03
Is China Resources Pharmaceutical Group Limited (HKG:3320) Trading At A 21% Discount?

Is China Resources Pharmaceutical Group Limited (HKG:3320) A Good Fit For Your Dividend Portfolio?

May 03
Is China Resources Pharmaceutical Group Limited (HKG:3320) A Good Fit For Your Dividend Portfolio?

Is China Resources Pharmaceutical Group (HKG:3320) A Risky Investment?

Apr 12
Is China Resources Pharmaceutical Group (HKG:3320) A Risky Investment?

Is China Resources Pharmaceutical Group Limited's (HKG:3320) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Mar 17
Is China Resources Pharmaceutical Group Limited's (HKG:3320) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Rendement voor aandeelhouders

3320HK PharmaceuticalsHK Markt
7D22.1%10.8%8.7%
1Y26.8%26.7%19.7%

Rendement versus industrie: 3320 kwam overeen met de Hong Kong Pharmaceuticals industrie, die het afgelopen jaar een rendement opleverde van 26.7 %.

Rendement versus markt: 3320 overtrof de Hong Kong markt, die het afgelopen jaar een rendement opleverde van 16.1 %.

Prijsvolatiliteit

Is 3320's price volatile compared to industry and market?
3320 volatility
3320 Average Weekly Movement5.0%
Pharmaceuticals Industry Average Movement5.2%
Market Average Movement7.1%
10% most volatile stocks in HK Market14.7%
10% least volatile stocks in HK Market3.6%

Stabiele aandelenkoers: 3320 heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van 3320 is het afgelopen jaar stabiel geweest.

Over het bedrijf

OpgerichtWerknemersCEOWebsite
200772,764Xiaosong Baiwww.crpharm.com

China Resources Pharmaceutical Group Limited, een investeringsmaatschappij, houdt zich bezig met onderzoek en ontwikkeling, productie, distributie en verkoop van farmaceutische en andere gezondheidsproducten op het Chinese vasteland en internationaal. Het bedrijf is actief in vier segmenten: Farmaceutische Productie, Farmaceutische Distributie, Farmaceutische Detailhandel en Overige. Het bedrijf biedt een scala aan chemische geneesmiddelen, Chinese geneesmiddelen en v, evenals voedings- en gezondheidsproducten voor verschillende therapeutische gebieden, waaronder cardiovasculaire en cerebrovasculaire, spijsverteringskanaal, metabolisme en endocriene, respiratoire, orthopedische, oncologische, medische voeding, gastro-enterologie, kindergeneeskunde, urogenitaal systeem, hoest en verkoudheid, anti-infectie, dermatologie, infuusoplossingen, enz.

China Resources Pharmaceutical Group Limited Samenvatting

Hoe verhouden de winst en inkomsten van China Resources Pharmaceutical Group zich tot de beurswaarde?
3320 fundamentele statistieken
MarktkapitalisatieHK$39.52b
Inkomsten(TTM)HK$4.17b
Inkomsten(TTM)HK$276.32b

9.5x

Koers/Winstverhouding

0.1x

P/S-verhouding

Is 3320 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
3320 resultatenrekening (TTM)
InkomstenCN¥250.48b
Kosten van inkomstenCN¥210.97b
BrutowinstCN¥39.51b
Overige uitgavenCN¥35.73b
InkomstenCN¥3.78b

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)0.60
Brutomarge15.77%
Nettowinstmarge1.51%
Schuld/Eigen Vermogen Verhouding77.1%

Hoe presteerde 3320 op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

2.9%

Huidig dividendrendement

39%

Uitbetalingsratio